On March 19, 2026, the FDA approved Wegovy HD — a new 7.2mg dose of semaglutide for chronic weight management. This isn't just a minor dose bump: at three times the original Wegovy dose, Wegovy HD delivers substantially more weight loss and positions semaglutide to compete directly with tirzepatide (Zepbound) on efficacy.
What Is Wegovy HD?
Wegovy HD is a higher-dose formulation of semaglutide, the same active ingredient in standard Wegovy (2.4mg) and Ozempic. Key facts:
- Brand name: Wegovy HD
- Generic name: Semaglutide 7.2mg
- Manufacturer: Novo Nordisk
- FDA approval date: March 19, 2026
- Indication: Chronic weight management in adults with BMI ≥30 (obesity) or ≥27 (overweight) with at least one weight-related comorbidity
- Administration: Once-weekly subcutaneous injection
- Delivery device: Pre-filled FlexTouch pen
STEP UP Trial Results
The approval was based on the STEP UP trial, a randomized, double-blind, placebo-controlled study in adults with obesity or overweight with comorbidities (without type 2 diabetes):
Primary Endpoints (72 weeks)
- Mean body weight loss: ~21% (ITT analysis) vs 2.1% placebo
- Patients achieving ≥20% weight loss: ~46%
- Patients achieving ≥15% weight loss: ~62%
- Patients achieving ≥10% weight loss: ~78%
- Patients achieving ≥5% weight loss: ~89%
How This Compares
| Medication | Weight Loss (ITT) | Trial Duration | Trial |
|---|---|---|---|
| Wegovy HD 7.2mg | ~21% | 72 weeks | STEP UP |
| Zepbound 15mg | ~22.5% | 72 weeks | SURMOUNT-1 |
| Wegovy 2.4mg | ~15% | 68 weeks | STEP 1 |
| Foundayo 17.2mg | ~11.2% | 72 weeks | ATTAIN-1 |
Wegovy HD at 21% nearly matches Zepbound's 22.5% — a remarkable achievement for a single-receptor agonist competing against a dual GLP-1/GIP agonist. While cross-trial comparisons have limitations (different populations, sites, and protocols), the numbers suggest these two medications are in the same weight-loss tier.
Dosing and Titration
For Patients New to Semaglutide
The full titration schedule from the beginning:
| Weeks | Dose |
|---|---|
| Weeks 1–4 | 0.25mg weekly |
| Weeks 5–8 | 0.5mg weekly |
| Weeks 9–12 | 1.0mg weekly |
| Weeks 13–16 | 1.7mg weekly |
| Weeks 17–20 | 2.4mg weekly |
| Weeks 21–24 | 3.6mg weekly |
| Weeks 25–28 | 5.4mg weekly |
| Week 29+ | 7.2mg weekly (maintenance) |
That's approximately 7 months of titration before reaching the full 7.2mg maintenance dose.
For Patients Already on Wegovy 2.4mg
If you're already stable on standard Wegovy:
| Weeks | Dose |
|---|---|
| Current | 2.4mg weekly (continue) |
| Weeks 1–4 | 3.6mg weekly |
| Weeks 5–8 | 5.4mg weekly |
| Week 9+ | 7.2mg weekly (maintenance) |
For patients already on 2.4mg, the additional titration takes about 2 months.
Who Is Wegovy HD For?
Wegovy HD is designed for patients who:
- Have plateaued on Wegovy 2.4mg — weight loss has stalled despite good adherence and lifestyle modifications
- Want maximum weight loss from a semaglutide-based therapy — 21% vs 15% is a meaningful difference for many patients
- Are already tolerating semaglutide well — if you have minimal side effects on 2.4mg, you're a good candidate for dose escalation
- Prefer to stay with a familiar medication rather than switching to tirzepatide (Zepbound)
Wegovy HD is not necessarily for:
- Patients who are achieving satisfactory results on standard Wegovy
- Patients struggling with GI side effects on current doses
- Patients starting GLP-1 therapy for the first time (start with standard titration)
Side Effects
The STEP UP trial showed a side effect profile similar to standard Wegovy, with modestly higher rates at the 7.2mg dose:
- Nausea: ~22% (vs ~20% at 2.4mg)
- Diarrhea: ~12% (vs ~10% at 2.4mg)
- Vomiting: ~10% (vs ~7% at 2.4mg)
- Constipation: ~11% (vs ~10% at 2.4mg)
- Discontinuation due to adverse events: ~8%
The incremental increase in side effects from 2.4mg to 7.2mg is surprisingly modest — likely because patients are already adapted to GLP-1 activation by the time they reach the higher dose. Most new side effects occur during the 3.6mg and 5.4mg titration steps. See our complete GLP-1 side effects guide for management strategies.
Pricing and Insurance
Novo Nordisk has not set a separate price for Wegovy HD — it follows the standard Wegovy pricing structure:
- List price: ~$1,349/month (same as Wegovy 2.4mg)
- Savings card: $25/month for commercially insured patients
- Medicare: Covered under Part D for weight management (2026); copays vary by plan
- Patient assistance: Novo Nordisk Patient Assistance Program for income-eligible uninsured patients
Insurance coverage is still being established. Many plans that currently cover Wegovy are expected to extend coverage to the 7.2mg dose, though some may require prior authorization showing inadequate response at 2.4mg.
Wegovy HD vs Zepbound
This is the comparison everyone is making:
| Feature | Wegovy HD 7.2mg | Zepbound 15mg |
|---|---|---|
| Mechanism | GLP-1 agonist only | GLP-1 + GIP dual agonist |
| Weight loss (ITT) | ~21% | ~22.5% |
| Dosing | Weekly injection | Weekly injection |
| List price | ~$1,349/mo | ~$1,086/mo |
| Manufacturer | Novo Nordisk | Eli Lilly |
| CV outcomes data | Yes (SELECT trial) | Pending (SURPASS-CVOT) |
| Time to maintenance dose | ~7 months from start | ~5 months from start |
Weight loss is effectively equivalent — a 1.5 percentage point difference is within the margin of cross-trial variability.
Cardiovascular data is where Wegovy HD has a significant advantage. The SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events (MACE) by 20% in patients with obesity. Tirzepatide's cardiovascular outcomes trial is still ongoing. For patients with established cardiovascular disease or high CV risk, this data may tip the decision toward semaglutide.
Cost slightly favors Zepbound at list price, though both are typically accessed through savings programs that bring costs to $25/month with commercial insurance.
Supply and Availability
Novo Nordisk has stated that Wegovy HD will be available through retail and specialty pharmacies beginning in April 2026. The company has invested in manufacturing capacity to avoid the supply constraints that plagued earlier Wegovy launches. However, some initial supply tightness is expected, particularly for the 7.2mg pens.
The Bottom Line
Wegovy HD 7.2mg represents a major step forward for semaglutide-based weight management. At ~21% body weight loss, it brings semaglutide into the same efficacy tier as tirzepatide and gives patients who've plateaued on standard Wegovy a meaningful next step. Combined with semaglutide's proven cardiovascular benefits, Wegovy HD is positioned as a premium option for patients seeking maximum weight loss from a well-established molecule.
If you're currently on Wegovy 2.4mg and considering the upgrade, talk to your healthcare provider about whether the additional titration and potential for increased side effects is worth the approximately 6 additional percentage points of weight loss.
Sources
- Novo Nordisk. STEP UP Phase 3 Trial Results. Semaglutide 7.2mg for Weight Management. 2025.
- FDA. Wegovy HD (semaglutide 7.2mg) Approval Letter. March 19, 2026.
- Novo Nordisk. Wegovy HD Prescribing Information. 2026.
- Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1)
- Lincoff AM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." N Engl J Med. 2023;389(24):2221-2232. (SELECT)